Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · see citing works

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

Goodman, A. M., Kato, S., Bazhenova, L., Patel, S. P., Frampton, G. M., Miller, V., Stephens, P. J., Daniels, G. A., & Kurzrock, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0386 · Cited by 2,264 · see citing works

Pan-cancer single-cell landscape of tumor-infiltrating T cells

Zheng, L., Qin, S., Si, W., Wang, A., Xing, B., Gao, R., Ren, X., Wang, L., Wu, X., Zhang, J., et al. (2021) · Science · doi:10.1126/science.abe6474 · Cited by 1,402 · see citing works

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360 · see citing works

CD36-mediated ferroptosis dampens intratumoral CD8+ T cell effector function and impairs their antitumor ability

Ma, X., Xiao, L., Liu, L., Ye, L., Pan, S., Bi, E., Wang, Q., Yang, M., Qian, J., & Yi, Q. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.02.015 · Cited by 1,022 · see citing works

ImmuCellAI: A Unique Method for Comprehensive T‐Cell Subsets Abundance Prediction and its Application in Cancer Immunotherapy

Miao, Y., Zhang, Q., Lei, Q., Luo, M., Xie, G., Wang, H., & Guo, A. (2020) · Advanced Science · doi:10.1002/advs.201902880 · Cited by 962 · see citing works

Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis

Turajlic, S., Litchfield, K., Xu, H., Rosenthal, R., McGranahan, N., Reading, J. L., Wong, Y. N. S., Rowan, A., Kanu, N., Bakir, M. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30516-8 · Cited by 909 · see citing works

Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance

Wu, W. E., Klockow, J., Zhang, M., Lafortune, F., Chang, E., Jin, L., Wu, Y., & Daldrup-Link, H. E. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105780 · Cited by 833 · see citing works

TIP: A Web Server for Resolving Tumor Immunophenotype Profiling

Xu, L., Deng, C., Pang, B., Zhang, X., Liu, W., Liao, G., Yuan, H., Peng, C., Li, F., Long, Z., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0689 · Cited by 698 · see citing works

Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers

Teo, M. Y., Seier, K., Ostrovnaya, I., Regazzi, A. M., Kania, B. E., Moran, M. M., Cipolla, C. K., Bluth, M. J., Chaim, J., Al-Ahmadie, H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.7740 · Cited by 544 · see citing works

Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β

Lan, Y., Zhang, D., Xu, C., Hance, K. W., Marelli, B., Qi, J., Yu, H., Qin, G., Sircar, A., Hernández, V. M., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan5488 · Cited by 494 · see citing works

Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis

Wang, P., Chen, Y., Song, S., Wang, T., Ji, W., Li, S., Liu, N., & Yan, C. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00730 · Cited by 473 · see citing works

Androgen receptor activity in T cells limits checkpoint blockade efficacy

Guan, X., Polesso, F., Wang, C., Sehrawat, A., Hawkins, R. M., Murray, S., THOMAS, G. V., Caruso, B., Thompson, R. F., Wood, M. A., et al. (2022) · Nature · doi:10.1038/s41586-022-04522-6 · Cited by 396 · see citing works

Expression profile of immune checkpoint genes and their roles in predicting immunotherapy response

Hu, F., Liu, C., Liu, L., Zhang, Q., & Guo, A. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa176 · Cited by 354 · see citing works

Overcoming resistance to tumor-targeted and immune-targeted therapies

Aldea, M., Andre, F., Marabelle, A., Dogan, S., Barlesi, F., & Soria, J.-C. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1638 · Cited by 311 · see citing works

Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma

Connor, A. A., Denroche, R. E., Jang, G. H., Timms, L. E., Kalimuthu, S. N., Selander, I., McPherson, T. A., Wilson, G. W., Chan‐Seng‐Yue, M., Borozan, I., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3916 · Cited by 285 · see citing works

Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients

Karachaliou, N., Gonzalez-Cao, M., Crespo, G., Drozdowskyj, A., Aldeguer, E., Gimenez-Capitan, A., Teixido, C., Molina-Vila, M. A., Viteri, S., De Los Llanos Gil, M., et al. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017749748 · Cited by 285 · see citing works

Cancer-Associated Fibroblasts Suppress CD8+ T-cell Infiltration and Confer Resistance to Immune-Checkpoint Blockade

Jenkins, L., Jungwirth, U., Avgustinova, A., Iravani, M., Mills, A., Haider, S. A., Harper, J. A., & Isacke, C. M. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4141 · Cited by 286 · see citing works

Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade

Gu, S. S., Zhang, W., Wang, X., Jiang, P., Traugh, N., Li, Z., Meyer, C., Stewig, B., Xie, Y., Bu, X., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0812 · Cited by 273 · see citing works

Sex-associated molecular differences for cancer immunotherapy

Ye, Y., Jing, Y., Liang, L., Mills, G. B., Diao, L., Liu, H., & Han, L. (2020) · Nature Communications · doi:10.1038/s41467-020-15679-x · Cited by 242 · see citing works

Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment

Zemek, R. M., de Jong, E., Chin, W. L., Schuster, I. S., Fear, V. S., Casey, T. H., Forbes, C., Dart, S., Leslie, C., Zaitouny, A., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav7816 · Cited by 207 · see citing works

The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors

Kim, K. H., Cho, J., Ku, B. M., Koh, J., Sun, J., Lee, S., Ahn, J. S., Cheon, J., Min, Y. J., Park, S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1449 · Cited by 205 · see citing works

MuPeXI: prediction of neo-epitopes from tumor sequencing data

Bjerregaard, A.-M., Nielsen, M., Hadrup, S. R., Szállási, Z., & Eklund, A. C. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2001-3 · Cited by 204 · see citing works

A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma

Pozniak, J., Pedri, D., Landeloos, E., Van Herck, Y., Antoranz, A., Vanwynsberghe, L., Nowosad, A., Roda, N., Makhzami, S., Bervoets, G., et al. (2024) · Cell · doi:10.1016/j.cell.2023.11.037 · Cited by 199 · see citing works

LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy

Li, G., Kryczek, I., Nam, J., Li, X., Li, S., Li, J., Wei, S., Grove, S., Vatan, L., Zhou, J., et al. (2021) · Nature Cell Biology · doi:10.1038/s41556-021-00672-3 · Cited by 194 · see citing works

Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy

Puig-Saus, C., Sennino, B., Peng, S., Wang, C. L., Pan, Z., Yuen, B., Purandare, B., An, D., Quach, B. B., Nguyen, D., et al. (2023) · Nature · doi:10.1038/s41586-023-05787-1 · Cited by 189 · see citing works

Immunotherapy Resistance by Inflammation-Induced Dedifferentiation

Mehta, A., Kim, Y. J., Robert, L., Tsoi, J., Comı́n-Anduix, B., Berent-Maoz, B., Cochran, A. J., Economou, J. S., Tumeh, P. C., Puig-Saus, C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1178 · Cited by 181 · see citing works

Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine

Conway, J. R., Kofman, E., Mo, S. S., Elmarakeby, H., & Van Allen, E. (2018) · Genome Medicine · doi:10.1186/s13073-018-0605-7 · Cited by 165 · see citing works

Aldo-keto reductases protect metastatic melanoma from ER stress-independent ferroptosis

Gagliardi, M., Cotella, D., Santoro, C., Corà, D., Barlev, N. A., Piacentini, M., & Corazzari, M. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2143-7 · Cited by 166 · see citing works

Synthetic lethality-mediated precision oncology via the tumor transcriptome

Lee, J. S., Nair, N. U., Dinstag, G., Chapman, L. M., Chung, Y., Wang, K., Sinha, S., Cha, H., Kim, D., Schperberg, A. V., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.030 · Cited by 154 · see citing works

The molecular feature of macrophages in tumor immune microenvironment of glioma patients

Zhang, H., Luo, Y., Wu, W., Zhang, L., Wang, Z., Dai, Z., Feng, S., Cao, H., Cheng, Q., & Liu, Z. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.08.019 · Cited by 148 · see citing works

PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies

Jin, M., Fang, J., Peng, J., Wang, X., Xing, P., Jia, K., Hu, J., Wang, D., Ding, Y., Wang, X., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02176-8 · Cited by 156 · see citing works

Machine learning-based identification of tumor-infiltrating immune cell-associated lncRNAs for improving outcomes and immunotherapy responses in patients with low-grade glioma

Zhang, N., Zhang, H., Wu, W., Zhou, R., Li, S., Wang, Z., Dai, Z., Zhang, L., Liu, F., Liu, Z., et al. (2022) · Theranostics · doi:10.7150/thno.74281 · Cited by 142 · see citing works

Characterization of Glycolysis-Associated Molecules in the Tumor Microenvironment Revealed by Pan-Cancer Tissues and Lung Cancer Single Cell Data

Wei, J., Huang, K., Chen, Z., Hu, M., Bai, Y., Lin, S., & Du, H. (2020) · Cancers · doi:10.3390/cancers12071788 · Cited by 141 · see citing works

Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers

Ock, C.-Y., Hwang, J., Keam, B., Kim, S.-B., Shim, J., Jang, H.-J., Park, S., Sohn, B. H., Cha, M., Ajani, J. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01018-0 · Cited by 135 · see citing works

Zika Virus Infects Human Sertoli Cells and Modulates the Integrity of the In Vitro Blood-Testis Barrier Model

Siemann, D. N., Strange, D. P., Maharaj, P. N., Shi, P., & Verma, S. (2017) · Journal of Virology · doi:10.1128/jvi.00623-17 · Cited by 135 · see citing works

Extracellular Vesicles in Cancer Drug Resistance: Roles, Mechanisms, and Implications

Yang, Q., Xu, J. B., Gu, J., Shi, H., Zhang, J., Zhang, J., Chen, Z., Fang, X., Zhu, T., & Zhang, X. (2022) · Advanced Science · doi:10.1002/advs.202201609 · Cited by 142 · see citing works

Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy

Mercogliano, M. F., Bruni, S., Mauro, F. L., Elizalde, P. V., & Schillaci, R. (2021) · Cancers · doi:10.3390/cancers13030564 · Cited by 134 · see citing works

Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers

Wu, H., Wang, Z., Zhao, Q., Chen, D., He, M.-M., Yang, L.-P., Wang, Y., Jin, Y., Ren, C., Luo, H., et al. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.10.116 · Cited by 127 · see citing works

Targeting immunosuppression by TGF-β1 for cancer immunotherapy

de Streel, G., & Lucas, S. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114697 · Cited by 129 · see citing works

Acquired resistance in cancer: towards targeted therapeutic strategies

Soragni, A., Knudsen, E. S., O’Connor, T. N., Tognon, C. E., Tyner, J. W., Gini, B., Kim, D., Bivona, T. G., Zang, X., Witkiewicz, A. K., et al. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00824-9 · Cited by 145 · see citing works

Neoantigens and genome instability: impact on immunogenomic phenotypes and immunotherapy response

Mardis, E. R. (2019) · Genome Medicine · doi:10.1186/s13073-019-0684-0 · Cited by 123 · see citing works

Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment

Saab, S., Zalzale, H., Rahal, Z., Khalifeh, Y., Sinjab, A. F., & Kadara, H. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00159 · Cited by 122 · see citing works

A High-Resolution Map of Human Enhancer RNA Loci Characterizes Super-enhancer Activities in Cancer

Chen, H., & Liang, H. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.020 · Cited by 121 · see citing works

Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?

Ziogas, D. C., Theocharopoulos, C., Koutouratsas, T., Haanen, J. B. A. G., & Gogas, H. J. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102499 · Cited by 119 · see citing works

Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma

Xiong, Z., Chan, S. L., Zhou, J., Vong, J. S. L., Kwong, T. T., Zeng, X., Wu, H., Cao, J., Tu, Y., Feng, Y., et al. (2023) · Gut · doi:10.1136/gutjnl-2022-328364 · Cited by 121 · see citing works

Vitamin D–VDR Signaling Inhibits Wnt/β-Catenin–Mediated Melanoma Progression and Promotes Antitumor Immunity

Muralidhar, S., Filia, A., Nsengimana, J., Poźniak, J., O'Shea, S. J., Diaz, J. M. S., Harland, M., Randerson‐Moor, J. A., Reichrath, J., Laye, J. P., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3927 · Cited by 113 · see citing works

Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma

Lepletier, A., Madore, J., O’Donnell, J. S., Johnston, R. L., Li, X.-Y., McDonald, E., Ahern, E. S., Kuchel, A., Eastgate, M. A., Pearson, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3925 · Cited by 111 · see citing works

Mechanisms of Drug Resistance in Melanoma

Winder, M. L., & Virós, A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_17 · Cited by 108 · see citing works

Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1

Lee, C., Bae, J.-H., Choe, E., Park, J., Park, S., Cho, H. J., Song, B., & Baek, M. (2022) · Theranostics · doi:10.7150/thno.68864 · Cited by 108 · see citing works

Multi-scale integrative analyses identify THBS2+ cancer-associated fibroblasts as a key orchestrator promoting aggressiveness in early-stage lung adenocarcinoma

Yang, H., Sun, B., Fan, L., Ma, W., Xu, K., Hall, S. R. R., Wang, Z., Schmid, R. A., Peng, R., Marti, T. M., et al. (2022) · Theranostics · doi:10.7150/thno.69590 · Cited by 106 · see citing works

Prognostic significance of immune landscape in tumour microenvironment of endometrial cancer

Li, B., & Wan, X. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15408 · Cited by 103 · see citing works

Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma

Yu, J., Yan, J., Guo, Q., Chi, Z., Tang, B., Zheng, B., Yu, J., Yin, T., Cheng, Z., Wu, X., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0475 · Cited by 100 · see citing works

Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer

Kobayashi, Y., Lim, S., & Yamaguchi, H. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.11.011 · Cited by 96 · see citing works

Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment

Onuma, A. E., Zhang, H., Huang, H., Williams, T. M., Noonan, A. M., & Tsung, A. (2020) · Gene Expression · doi:10.3727/105221620x15880179864121 · Cited by 92 · see citing works

PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy

Rolfes, V., Idel, C., Pries, R., Plötze‐Martin, K., Habermann, J. K., Gemoll, T., Bohnet, S., Latz, E., Ribbat‐Idel, J., Franklin, B. S., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25446 · Cited by 94 · see citing works

Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival

Wood, M. A., Weeder, B. R., David, J. K., Nellore, A., & Thompson, R. F. (2020) · Genome Medicine · doi:10.1186/s13073-020-00729-2 · Cited by 89 · see citing works

Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors

Iivanainen, S., Ahvonen, J., Knuuttila, A., Tiainen, S., & Koivunen, J. P. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000531 · Cited by 91 · see citing works

Pyroptosis-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with UCEC

Liu, J., Geng, R., Ni, S., Cai, L., Yang, S., Shao, F., & Bai, J. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.01.018 · Cited by 89 · see citing works

Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review

Tangella, L. P., Clark, M. E., & Gray, E. S. (2020) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2020.129736 · Cited by 82 · see citing works

Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis

Mo, J., Hu, X., Gu, L., Chen, B., Khadaroo, P. A., Shen, Z., Dong, L., Lv, Y., Chitumba, M. N., & Liu, J. (2020) · World Journal of Surgical Oncology · doi:10.1186/s12957-020-1792-4 · Cited by 85 · see citing works

Combining PARP Inhibition, Radiation, and Immunotherapy: A Possible Strategy to Improve the Treatment of Cancer?

Césaire, M., Thariat, J., Candéias, S. M., Stefan, D., Saintigny, Y., & Chevalier, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123793 · Cited by 84 · see citing works

Machine learning-based tumor-infiltrating immune cell-associated lncRNAs for predicting prognosis and immunotherapy response in patients with glioblastoma

Zhang, H., Zhang, N., Wu, W., Zhou, R., Li, S., Wang, Z., Dai, Z., Zhang, L., Liu, Z., Zhang, J., et al. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac386 · Cited by 83 · see citing works

Identification of Distinct Immune Subtypes in Colorectal Cancer Based on the Stromal Compartment

Shen, R., Li, P., Li, B., Zhang, B., Feng, L., & Cheng, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01497 · Cited by 78 · see citing works

News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors

Melaiu, O., Lucarini, V., Giovannoni, R., Fruci, D., & Gemignani, F. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.001 · Cited by 75 · see citing works

Therapeutic strategies to remodel immunologically cold tumors

Wang, M., Wang, S., Desai, J., Trapani, J. A., & Neeson, P. J. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1226 · Cited by 77 · see citing works

Single-cell N6-methyladenosine regulator patterns guide intercellular communication of tumor microenvironment that contribute to colorectal cancer progression and immunotherapy

Gao, Y., Wang, H., Chen, S., An, R., Chu, Y., Li, G., Wang, Y., Xie, X., & Zhang, J. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03395-7 · Cited by 71 · see citing works

An artificial intelligence network‐guided signature for predicting outcome and immunotherapy response in lung adenocarcinoma patients based on 26 machine learning algorithms

Zhang, N., Zhang, H., Liu, Z., Dai, Z., Wu, W., Zhou, R., Li, S., Wang, Z., Liang, X., Wen, J., et al. (2023) · Cell Proliferation · doi:10.1111/cpr.13409 · Cited by 69 · see citing works

Evolution of MHC-based technologies used for detection of antigen-responsive T cells

Bentzen, A. K., & Hadrup, S. R. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1971-5 · Cited by 69 · see citing works

The Landscape of Tumor Fusion Neoantigens: A Pan-Cancer Analysis

Wei, Z., Zhou, C., Zhang, Z., Guan, M., Zhang, C., Liu, Z., & Liu, Q. (2019) · iScience · doi:10.1016/j.isci.2019.10.028 · Cited by 67 · see citing works

Histone modifications in drug-resistant cancers: From a cancer stem cell and immune evasion perspective

Jin, M., & Jeong, K. W. (2023) · Experimental and Molecular Medicine · doi:10.1038/s12276-023-01014-z · Cited by 54 · see citing works

Characterization of the prognostic and oncologic values of ITGB superfamily members in pancreatic cancer

Zhuang, H., Zhou, Z., Ma, Z., Li, Z., Liu, C., Huang, S., Zhang, C., & Hou, B. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15990 · Cited by 60 · see citing works

NOTCH3 is a Prognostic Factor and Is Correlated With Immune Tolerance in Gastric Cancer

Cui, Y., Li, Q., Li, W., Wang, Y., Lv, F., Shi, X., Tang, Z., Shen, Z., Hou, Y., Zhang, H., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.574937 · Cited by 62 · see citing works

Pan‐cancer analyses reveal molecular and clinical characteristics of cuproptosis regulators

Wu, C., Tan, J., Wang, X., Qin, C., Long, W., Pan, Y., Li, Y., & Liu, Q. (2022) · iMeta · doi:10.1002/imt2.68 · Cited by 59 · see citing works

Emerging biomarkers for cancer immunotherapy in melanoma

Axelrod, M. L., Johnson, D. B., & Balko, J. M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.09.004 · Cited by 58 · see citing works

DNA methylation regulator-mediated modification patterns and tumor microenvironment characterization in gastric cancer

Qi, M., Lu, Y., Ruan, D., Yu, K., Chen, Y., Xiao, M., Wang, Y., Liu, Z., Xu, R., Ju, H., et al. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.03.023 · Cited by 57 · see citing works

The COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma

Kim, S.-H., Roszik, J., Cho, S.-N., Ogata, D., Milton, D. R., Peng, W., Menter, D. G., Ekmekçioglu, S., & Grimm, E. A. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1163 · Cited by 56 · see citing works

EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinoma

Huang, W., Lin, A., Luo, P., Liu, Y., Xu, W., Zhu, W., Wei, T., Lyu, Q., Guo, L., & Zhang, J. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-0207-6 · Cited by 55 · see citing works

Transcriptional Spatial Profiling of Cancer Tissues in the Era of Immunotherapy: The Potential and Promise

Nerurkar, S. N., Goh, D. L. M., Cheung, C. C. L., Nga, P. Q. Y., Lim, J. C. T., & Yeong, J. P.-S. (2020) · Cancers · doi:10.3390/cancers12092572 · Cited by 55 · see citing works

Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance

Yang, M., Lin, C.-H., Wang, Y., Chen, K., Zhang, H., & Li, W. (2022) · Genome Medicine · doi:10.1186/s13073-022-01079-x · Cited by 55 · see citing works

The mechanical phenotypic plasticity of melanoma cell: an emerging driver of therapy cross-resistance

Diazzi, S., Tartare‐Deckert, S., & Deckert, M. (2023) · Oncogenesis · doi:10.1038/s41389-023-00452-8 · Cited by 57 · see citing works

Navigating the immune landscape with plasma cells: A pan‐cancer signature for precision immunotherapy

Ye, B., Jiang, A., Feng, L., Wang, C., Liang, X., & Zhang, P. (2024) · BioFactors · doi:10.1002/biof.2142 · Cited by 52 · see citing works

Immune Infiltrating Cells-Derived Risk Signature Based on Large-scale Analysis Defines Immune Landscape and Predicts Immunotherapy Responses in Glioma Tumor Microenvironment

Zhang, N., Zhang, H., Wang, Z., Dai, Z., Zhang, X., Cheng, Q., & Liu, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.691811 · Cited by 49 · see citing works

Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma

Poźniak, J., Nsengimana, J., Laye, J. P., O'Shea, S. J., Diaz, J. M. S., Droop, A., Filia, A., Harland, M., Davies, J. R., Mell, T., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2864 · Cited by 50 · see citing works

Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non‐small cell lung cancer

Zhang, W., Shi, F., Kong, Y., Li, Y., Sheng, C., Wang, S., & Wang, Q. (2021) · Cancer Medicine · doi:10.1002/cam4.4472 · Cited by 48 · see citing works

Development and Validation of a DNA Methylation-related Classifier of Circulating Tumour Cells to Predict Prognosis and to provide a therapeutic strategy in Lung Adenocarcinoma

Gu, X., Huang, X., Zhang, X., & Wang, C. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.75284 · Cited by 49 · see citing works

Temporally restricted activation of IFNβ signaling underlies response to immune checkpoint therapy in mice

Zemek, R. M., Chin, W. L., Fear, V. S., Wylie, B., Casey, T. H., Forbes, C., Tilsed, C. M., Boon, L., Guo, B. B., Bosco, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32567-8 · Cited by 48 · see citing works

Succinate preserves CD8+ T cell fitness to augment antitumor immunity

Ma, K., Cheng, H., Wang, L., Xiao, H., Liu, F., Yang, Y. T., Xiao, Z., Tang, K., Li, S., Wang, G., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.07.017 · Cited by 52 · see citing works

Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection

Banna, G. L., Passiglia, F., Colonese, F., Canova, S., Menis, J., Addeo, A., Russo, A. D., & Cortinovis, D. L. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.06.016 · Cited by 48 · see citing works

Heterogeneity induced GZMA-F2R communication inefficient impairs antitumor immunotherapy of PD-1 mAb through JAK2/STAT1 signal suppression in hepatocellular carcinoma

Gao, Y., Xu, Q., Li, X., Guo, Y. L., Zhang, B., Jin, Y., Zhu, C., Shen, Y., Yang, P., Shi, Y., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04654-7 · Cited by 47 · see citing works

Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes

Lu, T., Wang, S., Xu, L., Zhou, Q., Singla, N., Gao, J., Manna, S., Pop, L. M., Xie, Z., Chen, M., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aaz3199 · Cited by 48 · see citing works

Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma

Lorenzo, S. D., Tovoli, F., & Trevisani, F. (2022) · Cancers · doi:10.3390/cancers14194616 · Cited by 51 · see citing works

Tumor-Secreted IFI35 Promotes Proliferation and Cytotoxic Activity of CD8+ T Cells Through PI3K/Akt/mTOR Signaling Pathway in Colorectal Cancer

Li, P., Zhou, D., Chen, D., Cheng, Y., Chen, Y., Lin, Z.-S., Zhang, X., Huang, Z., Cai, J., Huang, W., et al. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-023-00930-6 · Cited by 48 · see citing works

Pan-cancer evaluation of regulated cell death to predict overall survival and immune checkpoint inhibitor response

Zhang, W., Zhu, Y., Liu, H., Zhang, Y., Liu, H., Adegboro, A. A., Dang, R., Dai, L., Wanggou, S., & Li, X. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00570-5 · Cited by 49 · see citing works

Prognostic values and immune suppression of the S100A family in pancreatic cancer

Zhuang, H., Chen, X., Dong, F., Zhang, Z., Zhou, Z., Ma, Z., Huang, S., Chen, B., Zhang, C., & Hou, B. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16343 · Cited by 45 · see citing works

Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance

Voronova, V., Vislobokova, A., Mutig, K., Samsonov, M., Peskov, K. V., Sekacheva, M. I., Materenchuk, M. Y., Bunyatyan, N. D., & Lebedeva, S. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1035884 · Cited by 46 · see citing works

Novel immune checkpoint targets: A promising therapy for cancer treatments

Patwekar, M. F., Sehar, N., Patwekar, F., Medikeri, A., Ali, S., Aldossri, R. M., & Rehman, M. U. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111186 · Cited by 44 · see citing works

Role of extracellular matrix architecture and signaling in melanoma therapeutic resistance

Popovic, A., & Tartare‐Deckert, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.924553 · Cited by 42 · see citing works

Interleukin-16 enhances anti-tumor immune responses by establishing a Th1 cell-macrophage crosstalk through reprogramming glutamine metabolism in mice

Wen, Z., Liu, T., Xu, X., Acharya, N., Shen, Z., Lu, Y., Xu, J., Guo, K., Shen, S., Zhao, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57603-1 · Cited by 46 · see citing works

Identification of gene expression profiles and immune cell infiltration signatures between low and high tumor mutation burden groups in bladder cancer

Wu, Z., Wang, M.-R., Liu, Q., Liu, Y., Zhu, K., Chen, L., Guo, H., Li, Y., & Shi, B. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.39056 · Cited by 43 · see citing works

The GENCODE exome: sequencing the complete human exome

Coffey, A. J., Kokocinski, F., Calafato, M., Scott, C., Palta, P., Drury, E., Joyce, C. J., LeProust, E. M., Harrow, J., Hunt, S. E., et al. (2011) · European Journal of Human Genetics · doi:10.1038/ejhg.2011.28 · Cited by 64 · see citing works

The current landscape of clinical exome and genome reanalysis in the U.S.

Frees, M., Carter, J. N., Wheeler, M. T., & Reuter, C. M. (2024) · Journal of Genetic Counseling · doi:10.1002/jgc4.1968 · Cited by 5 · see citing works

Clinical Exome Performance for Reporting Secondary Genetic Findings

Park, J. Y., Clark, P., Londin, E. R., Sponziello, M., Kricka, L. J., & Fortina, P. M. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2014.231456 · Cited by 37 · see citing works

Exome Sequencing in Mendelian Disorders

Lee, J. (2010) · Journal of genetic medicine · doi:10.5734/jgm.2010.7.2.119 · Cited by 1 · see citing works

Diagnostic Exome Sequencing — Are We There Yet?

Mefford, H. C. (2012) · New England Journal of Medicine · doi:10.1056/nejme1211659 · Cited by 24 · see citing works